Enemem, >>> Which prospective partners are still viable? <<<
That's what I'd like to know also. Neuro said the pain oriented mid-caps like Endo, Cephalon, and Purdue were all going in other directions, away from pain. I suppose that leaves us with 'Reckitt Benckiser'.